Anaptysbio Stock Performance

ANAB Stock  USD 54.83  1.13  2.10%   
On a scale of 0 to 100, AnaptysBio holds a performance score of 13. The firm shows a Beta (market volatility) of 0.0702, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AnaptysBio's returns are expected to increase less than the market. However, during the bear market, the loss of holding AnaptysBio is expected to be smaller as well. Please check AnaptysBio's mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether AnaptysBio's price patterns will revert.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
2.11
Five Day Return
0.38
Year To Date Return
21.98
Ten Year Return
222.53
All Time Return
222.53
1
The Bull Case For AnaptysBio Could Change Following Jemperli Legal Clash With GSK Subsidiary
12/02/2025
2
Disposition of 6360 shares by Dennis Mulroy of AnaptysBio at 45.2062 subject to Rule 16b-3
12/16/2025
3
Disposition of 10000 shares by Eric Loumeau of AnaptysBio at 51.0 subject to Rule 16b-3
12/22/2025
4
AnaptysBio Insider Paul Lizzul Sells 1,500 Shares
12/24/2025
5
Disposition of 1500 shares by Lizzul Paul F. of AnaptysBio at 50.0 subject to Rule 16b-3
12/26/2025
6
Disposition of 7287 shares by Eric Loumeau of AnaptysBio subject to Rule 16b-3
01/02/2026
7
Disposition of 2983 shares by Eric Loumeau of AnaptysBio at 43.26 subject to Rule 16b-3
01/05/2026
8
Acquisition by Orwin John A of 6000 shares of AnaptysBio subject to Rule 16b-3
01/06/2026
9
Anaptys Files Motion to Dismiss Tesaros Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
01/08/2026
10
Disposition of 11000 shares by Marquet Magda of AnaptysBio at 26.11 subject to Rule 16b-3
01/15/2026
11
AnaptysBio Director Magda Marquet Sells 11,000 Shares - MarketBeat
01/16/2026
12
Assessing AnaptysBio Valuation As Technical Strength Meets Improving Profitability Prospects
01/22/2026
13
Disposition of 2017 shares by Eric Loumeau of AnaptysBio at 45.11 subject to Rule 16b-3
01/30/2026
14
Acquisition by Daniel Faga of 26838 shares of AnaptysBio subject to Rule 16b-3
02/04/2026
15
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4
02/12/2026
Begin Period Cash Flow36 M
Total Cashflows From Investing Activities95.4 M

AnaptysBio Relative Risk vs. Return Landscape

If you would invest  3,961  in AnaptysBio on November 21, 2025 and sell it today you would earn a total of  1,522  from holding AnaptysBio or generate 38.42% return on investment over 90 days. AnaptysBio is currently generating 0.6117% in daily expected returns and assumes 3.4837% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than AnaptysBio, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days AnaptysBio is expected to generate 4.66 times more return on investment than the market. However, the company is 4.66 times more volatile than its market benchmark. It trades about 0.18 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.

AnaptysBio Target Price Odds to finish over Current Price

The tendency of AnaptysBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 54.83 90 days 54.83 
under 4
Based on a normal probability distribution, the odds of AnaptysBio to move above the current price in 90 days from now is under 4 (This AnaptysBio probability density function shows the probability of AnaptysBio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days AnaptysBio has a beta of 0.0702. This suggests as returns on the market go up, AnaptysBio average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding AnaptysBio will be expected to be much smaller as well. Additionally AnaptysBio has an alpha of 0.8128, implying that it can generate a 0.81 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   AnaptysBio Price Density   
       Price  

Predictive Modules for AnaptysBio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AnaptysBio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
50.7654.2657.76
Details
Intrinsic
Valuation
LowRealHigh
53.8757.3760.87
Details
Naive
Forecast
LowNextHigh
51.8355.3358.84
Details
12 Analysts
Consensus
LowTargetHigh
61.8067.9275.39
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as AnaptysBio. Your research has to be compared to or analyzed against AnaptysBio's peers to derive any actionable benefits. When done correctly, AnaptysBio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in AnaptysBio.

AnaptysBio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. AnaptysBio is not an exception. The market had few large corrections towards the AnaptysBio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AnaptysBio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AnaptysBio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.81
β
Beta against Dow Jones0.07
σ
Overall volatility
5.07
Ir
Information ratio 0.23

AnaptysBio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AnaptysBio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AnaptysBio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
AnaptysBio appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M.
AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4

AnaptysBio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AnaptysBio Stock often depends not only on the future outlook of the current and potential AnaptysBio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AnaptysBio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding28.4 M
Cash And Short Term Investments385.4 M

AnaptysBio Fundamentals Growth

AnaptysBio Stock prices reflect investors' perceptions of the future prospects and financial health of AnaptysBio, and AnaptysBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnaptysBio Stock performance.

About AnaptysBio Performance

By analyzing AnaptysBio's fundamental ratios, stakeholders can gain valuable insights into AnaptysBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnaptysBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnaptysBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.27)(0.28)
Return On Capital Employed(0.24)(0.25)
Return On Assets(0.27)(0.28)
Return On Equity(1.84)(1.94)

Things to note about AnaptysBio performance evaluation

Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
AnaptysBio appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M.
AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4
Evaluating AnaptysBio's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate AnaptysBio's stock performance include:
  • Analyzing AnaptysBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnaptysBio's stock is overvalued or undervalued compared to its peers.
  • Examining AnaptysBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating AnaptysBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnaptysBio's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of AnaptysBio's stock. These opinions can provide insight into AnaptysBio's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating AnaptysBio's stock performance is not an exact science, and many factors can impact AnaptysBio's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data